Minimum Dose CT Post Lung Biopsy

Lung Cancer Clinical Trial

Official title:

Can Minimum Dose CT Post Lung Biopsy Predict Patient Outcome?

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00188162
• Other study ID #: 03-0898
• Status: Completed
• Phase: Phase 1
• First received: September 12, 2005
• Last updated: April 20, 2007
• Start date: January 2004
• Est. completion date: September 2005

Study information

• Verified date: September 2005
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The aim is to evaluate whether Minimum Dose CT (MnDCT) is useful in the management of patients post Lung Biopsy

Description:

Patients post Lung Biopsy have a chest X-ray (CXR) and a MnDCT post lung biopsy. Both studies are compared for the detection of a pneumothorax

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: September 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

• All Patients having a lung biopsy

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Lung Cancer

Intervention

Device:
• CT

Locations

Country	Name	City	State
Canada	Toronto General Hospital	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
University Health Network, Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of Pneumothorax